GeneHealth - Your precision medicine

Polycythemia Vera

Disease Details

Family Health Simplified

Buy Membership

Description: Polycythemia vera is a rare blood disorder in which the body produces an excessive number of red blood cells, leading to increased blood viscosity and associated complications.
Type: Polycythemia vera is classified as a myeloproliferative neoplasm. It is not typically inherited in a simple Mendelian fashion, but it is primarily associated with a somatic mutation in the JAK2 gene, which occurs during a person's lifetime and is not passed from parent to child.
Signs And Symptoms: People with polycythemia vera can be asymptomatic. Clinical symptoms of polycythemia vera are mostly due to hyperviscosity of blood. A classic symptom of polycythemia vera is pruritus or itching, particularly after exposure to warm water (such as when taking a bath), which may be due to abnormal histamine release or prostaglandin production. Such itching is present in approximately 40% of patients with polycythemia vera. Gouty arthritis may be present in up to 20% of patients. Peptic ulcer disease is also common in patients with polycythemia vera; most likely due to increased histamine from mast cells, but may be related to an increased susceptibility to infection with the ulcer-causing bacterium H. pylori.A classic symptom of polycythemia vera (and the related myeloproliferative disease essential thrombocythemia) is erythromelalgia. This is a burning pain in the hands or feet, usually accompanied by a reddish or bluish coloration of the skin. Erythromelalgia is caused by an increased platelet count or increased platelet "stickiness" (aggregation), resulting in the formation of tiny blood clots in the vessels of the extremity; it responds rapidly to treatment with aspirin. Splenomegaly may cause the spleen to be palpable in some patients, which has been reported by Lee et al. (2022) to be associated with both the V617F mutation and the development of myelofibrosis.
Prognosis: Polycythemia vera (PV) is a chronic blood disorder characterized by the overproduction of red blood cells. The prognosis for PV varies:

- Life Expectancy: Patients can live for many years with appropriate treatment. Median survival times can exceed a decade, and some patients may live 20 years or more.
- Complications: PV can lead to complications such as blood clots, stroke, heart attack, or transformation into myelofibrosis or acute leukemia.
- Treatment Impact: Regular phlebotomy, medication to reduce blood cell production, and low-dose aspirin can improve outcomes and reduce symptom burden.
Onset: Polycythemia vera is a rare blood disorder characterized by the overproduction of red blood cells. The onset of polycythemia vera can vary, but it typically occurs in adults over the age of 60. However, it can also develop in younger individuals. Symptoms can sometimes be subtle and develop gradually over many years.
Prevalence: The prevalence of polycythemia vera is estimated to be approximately 44 to 57 cases per 100,000 people. This rare blood disorder is characterized by an increased number of red blood cells and can lead to complications such as blood clots.
Epidemiology: Polycythemia vera occurs in all age groups, although the incidence increases with age. One study found the median age at diagnosis to be 60 years, while a Mayo Clinic study in Olmsted County, Minnesota found that the highest incidence was in people aged 70–79 years. The overall incidence in the Minnesota population was 1.9 per 100,000 person-years, and the disease was more common in men than women. A cluster around a toxic site was confirmed in northeast Pennsylvania in 2008.
Intractability: Polycythemia vera is considered a chronic and incurable disease. Treatment can manage symptoms, reduce the risk of complications, and improve quality of life but does not cure the disease.
Disease Severity: Polycythemia vera is a chronic, progressive blood disorder characterized by the overproduction of red blood cells. Its severity can vary widely among individuals:

1. **Mild**: Some individuals may have no symptoms or only mild symptoms for years, such as headaches, dizziness, and fatigue.

2. **Moderate**: With disease progression, symptoms may become more pronounced, including an increase in blood viscosity leading to more severe headaches, blurred vision, and high blood pressure.

3. **Severe**: In advanced cases, complications can include an increased risk of blood clots, which can lead to stroke or heart attack. There may also be a risk of transforming into myelofibrosis or acute myeloid leukemia.

Severe cases require close medical management to mitigate risks and manage symptoms effectively.
Healthcare Professionals: Disease Ontology ID - DOID:8997
Pathophysiology: Polycythemia vera (PV), being a primary polycythemia (increase in the fraction of volume occupied by red cells in the blood), is caused by neoplastic proliferation and maturation of erythroid, megakaryocytic and granulocytic elements to produce what is referred to as panmyelosis. In contrast to secondary polycythemias, PV is associated with a low serum level of the hormone erythropoietin (EPO). Instead, PV cells often carry activating mutation in a tyrosine kinase–encoding gene, JAK2, which acts in signaling pathways of the EPO receptor, making those cells proliferate independently from EPO.
Carrier Status: Polycythemia vera is not a condition associated with carrier status because it is not a genetic disorder inherited through recessive or dominant alleles. Instead, it is a type of blood cancer, specifically a myeloproliferative neoplasm, that typically results from a mutation in the JAK2 gene. This mutation usually occurs spontaneously (acquired) rather than being inherited.
Mechanism: Polycythemia vera (PV) is a type of blood cancer characterized by an overproduction of red blood cells. The overproduction can also extend to white blood cells and platelets. This leads to increased blood viscosity and risk of thrombosis. The primary mechanism driving PV involves the clonal proliferation of hematopoietic stem cells.

**Molecular Mechanisms:**

1. **JAK2 Mutation:** The most common mutation associated with PV is in the JAK2 gene, specifically JAK2 V617F. This mutation affects the Janus kinase 2 (JAK2) protein, which plays a crucial role in regulating blood cell production. The JAK2 V617F mutation results in constitutive activation of the JAK-STAT pathway, leading to uncontrolled cell proliferation and survival.

2. **Erythropoietin Receptor:** Normally, erythropoietin (a hormone) binds to its receptor to regulate red blood cell production. In PV, the JAK2 mutation makes progenitor cells hypersensitive to erythropoietin, exacerbating the overproduction of red blood cells.

3. **Other Mutations:** Though less common, mutations in other genes such as TET2, ASXL1, and EZH2 can also contribute to PV. These mutations typically affect the epigenetic regulation of gene expression, further promoting abnormal cellular proliferation and differentiation.

Understanding these molecular mechanisms is crucial for diagnosing PV and developing targeted therapies.
Treatment: Untreated, polycythemia vera can be fatal, with the median survival in patients being 1.5-3 years. Data on the effect of life-span of an individual with treated polycythemia vera is inconclusive due to the rarity of the disease. Studies show the median survival rate of controlled Polycythemia Vera ranges from 10 to 20 years; however, most observations are of people diagnosed in their 60s. Patients live close to a normal life expectancy.Frequent blood withdrawals (phlebotomy) are one form of treatment, which often may be combined with other therapies. The removal of blood from the body induces iron deficiency, thereby decreasing the hemoglobin / hematocrit level, and reducing the risk of blood clots. Phlebotomy is typically performed to bring their hematocrit (red blood cell percentage) down below 45 for men or 42 for women. It has been observed that phlebotomy also reduces cognitive impairment.Medications are also used which reduce the number of red blood cells. These include hydroxyurea and interferon therapy, among others. The tendency of some practitioners to avoid chemotherapy if possible, especially in young patients, is a result of research indicating possible increased risk of transformation to acute myelogenous leukemia (AML). While hydroxyurea is considered a safer chemotherapy in this aspect, there is still some debate about its long-term safety.There are indications that the lung cancer drug erlotinib may be an additional treatment option for those with certain genetic markers.Ruxolitinib (brand name Jakafi), a Janus kinase 2 (JAK2) inhibitor, is also used to treat polycythemia.Ropeginterferon alfa-2b (Besremi) was approved for medical use in the European Union in February 2019, and in the United States in November 2021. Ropeginterferon alfa-2b is the first medication approved by the U.S. Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera. Interferon alfa-2b is also used.
Compassionate Use Treatment: Polycythemia vera (PV) is a type of blood cancer characterized by the overproduction of red blood cells. Compassionate use and off-label or experimental treatments for PV may include:

1. **Ruxolitinib (Jakafi)**: Originally approved for myelofibrosis and certain other disorders, ruxolitinib has been used off-label for PV patients who are refractory to or intolerant of hydroxyurea.

2. **Interferon-alpha (Pegylated Interferon-alpha)**: Although not specifically approved for PV, pegylated interferon-alpha is used off-label for patients, especially younger ones, who may benefit from this treatment.

3. **Ruxolitinib in combination with other therapies**: Clinical trials may explore combinations of ruxolitinib with other agents to enhance its efficacy in PV.

4. **Histone deacetylase inhibitors (e.g., Givinostat)**: Experimental treatments like Givinostat are currently being studied in clinical trials for their potential effectiveness in treating PV.

5. **Ropeginterferon alfa-2b (Besremi)**: This is an interferon-based treatment that has been approved in Europe and is under study in other regions for long-term treatment of PV.

These off-label and experimental treatments typically require close monitoring under the supervision of a hematologist or an oncologist, often within the context of clinical trials or specialized care programs.
Lifestyle Recommendations: Lifestyle recommendations for managing polycythemia vera include:

1. **Stay Hydrated**: Drinking plenty of fluids can help prevent blood from becoming too thick.
2. **Exercise Regularly**: Engage in moderate physical activity to improve circulation and overall health.
3. **Avoid Tobacco**: Smoking can increase the risk of blood clots and other complications.
4. **Manage Stress**: Utilize stress-reduction techniques such as meditation, yoga, or deep-breathing exercises.
5. **Healthy Diet**: Follow a balanced diet rich in fruits, vegetables, and whole grains, while limiting red meat and saturated fats.
6. **Regular Check-ups**: Adhere to routine medical follow-ups and screenings to monitor the condition and adjust treatment as necessary.
7. **Skin Care**: Protect skin from excessive sun exposure and injury, as the condition can cause sensitivity.

Always consult with a healthcare provider for personalized advice and management plans tailored to individual needs.
Medication: Polycythemia vera is primarily managed with treatments aimed at reducing blood thickness and volume, and controlling symptoms. The main medications include:

1. **Hydroxyurea**: A cytoreductive agent used to decrease the production of blood cells in the bone marrow.
2. **Interferon-alpha**: Often used for younger patients or those who cannot tolerate hydroxyurea, it helps reduce blood cell production.
3. **Ruxolitinib (Jakafi)**: A JAK1 and JAK2 inhibitor used for patients who are resistant or intolerant to hydroxyurea.
4. **Aspirin**: Low-dose aspirin is commonly prescribed to reduce the risk of blood clots.
5. **Phlebotomy**: Not a medication, but a procedure to remove blood from the body to reduce blood volume and viscosity.

Consultation with a healthcare provider is crucial to tailor the treatment to the individual’s specific medical condition and needs.
Repurposable Drugs: Polycythemia vera is a type of blood cancer that leads to an abnormal increase in red blood cells. Some repurposable drugs that have been used or explored for treating polycythemia vera include:

1. **Ruxolitinib (Jakafi)**: Originally approved for myelofibrosis, it is also used in polycythemia vera patients who are resistant or intolerant to hydroxyurea.
2. **Interferon-alpha**: Although primarily used for viral infections and certain cancers, it has shown effectiveness in reducing blood counts in polycythemia vera.
3. **Hydroxyurea**: A chemotherapy drug that has been used for a long time to control blood counts in polycythemia vera.

These drugs, while primarily developed for other conditions, have shown efficacy in managing polycythemia vera symptoms and complications.
Metabolites: Polycythemia vera is a type of blood cancer characterized by the overproduction of red blood cells. In the context of metabolites, key metabolites in polycythemia vera include elevated levels of erythropoietin and abnormal hematocrit levels. Additionally, the JAK2 V617F mutation often leads to alterations in signaling pathways and associated metabolites. Sodium, potassium, and other blood electrolytes may also show abnormalities due to changes in blood cell production.
Nutraceuticals: Polycythemia vera is primarily managed through phlebotomy and medications. Nutraceuticals (food-derived products offering health benefits) are not standard treatments, but antioxidant-rich foods and supplements may support overall health. Vitamin D, omega-3 fatty acids, and green tea extracts are sometimes considered for their potential anti-inflammatory properties. Always consult healthcare providers before starting any supplement regimen. Nanotechnology applications are still under research and are not yet a standard part of treatment for polycythemia vera.
Peptides: Polycythemia vera (PV) is not typically associated with treatments involving peptides or nanotechnology (nan). The primary treatments for PV usually involve phlebotomy, medications like hydroxyurea or ruxolitinib, and low-dose aspirin to manage symptoms and reduce the risk of thrombotic events. Peptide-based treatments or nanotechnology-based interventions are not standard therapies for PV at this time.